WO1994002122A1 - Lymphatic delivery composition - Google Patents
Lymphatic delivery composition Download PDFInfo
- Publication number
- WO1994002122A1 WO1994002122A1 PCT/GB1993/001596 GB9301596W WO9402122A1 WO 1994002122 A1 WO1994002122 A1 WO 1994002122A1 GB 9301596 W GB9301596 W GB 9301596W WO 9402122 A1 WO9402122 A1 WO 9402122A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- particle
- particles
- modifying agent
- active agent
- less
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6504329A JPH08501534A (en) | 1992-07-28 | 1993-07-28 | Lymphatic delivery composition |
AU47175/93A AU4717593A (en) | 1992-07-28 | 1993-07-28 | Lymphatic delivery composition |
GB9500063A GB2283422B (en) | 1992-07-28 | 1993-07-28 | Lymphatic delivery composition |
US08/374,671 US5792475A (en) | 1992-07-28 | 1993-07-28 | Lymphatic delivery composition |
DE69321839T DE69321839T2 (en) | 1992-07-28 | 1993-07-28 | COMPOSITION FOR LYMPHATIC APPLICATION |
DK93917936T DK0652746T3 (en) | 1992-07-28 | 1993-07-28 | Lymphatic delivery composition |
ES93917936T ES2124791T3 (en) | 1992-07-28 | 1993-07-28 | RELEASE COMPOSITION IN THE LYMPHATIC SYSTEM OF AN ACTIVE AGENT. |
EP93917936A EP0652746B1 (en) | 1992-07-28 | 1993-07-28 | Lymphatic delivery composition |
NO950238A NO307169B1 (en) | 1992-07-28 | 1995-01-23 | Mixture for delivery of drug to the lymphatic system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9216082.9 | 1992-07-28 | ||
GB929216082A GB9216082D0 (en) | 1992-07-28 | 1992-07-28 | Lymphatic delivery composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994002122A1 true WO1994002122A1 (en) | 1994-02-03 |
Family
ID=10719471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1993/001596 WO1994002122A1 (en) | 1992-07-28 | 1993-07-28 | Lymphatic delivery composition |
Country Status (10)
Country | Link |
---|---|
US (2) | US5792475A (en) |
EP (1) | EP0652746B1 (en) |
JP (1) | JPH08501534A (en) |
AU (1) | AU4717593A (en) |
DE (1) | DE69321839T2 (en) |
DK (1) | DK0652746T3 (en) |
ES (1) | ES2124791T3 (en) |
GB (2) | GB9216082D0 (en) |
NO (1) | NO307169B1 (en) |
WO (1) | WO1994002122A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0601619A2 (en) * | 1992-12-04 | 1994-06-15 | NanoSystems L.L.C. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
WO1995003357A1 (en) * | 1993-07-23 | 1995-02-02 | Massachusetts Institute Of Technology | Biodegradable particles |
WO1995022963A1 (en) * | 1994-02-28 | 1995-08-31 | Medinova Medical Consulting Gmbh | Drug targeting system, method for preparing same and its use |
US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5611344A (en) * | 1996-03-05 | 1997-03-18 | Acusphere, Inc. | Microencapsulated fluorinated gases for use as imaging agents |
EP0859604A1 (en) * | 1995-09-29 | 1998-08-26 | NanoSystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
US6007845A (en) * | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US8097282B2 (en) | 1995-02-24 | 2012-01-17 | Alkermes Pharma Ireland Limited | Methods of administering liquid droplet aerosols of nanoparticulate drugs |
US9084727B2 (en) | 2011-05-10 | 2015-07-21 | Bend Research, Inc. | Methods and compositions for maintaining active agents in intra-articular spaces |
US9757464B2 (en) | 2009-03-05 | 2017-09-12 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070116761A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US6511477B2 (en) * | 1997-03-13 | 2003-01-28 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
US6443949B2 (en) * | 1997-03-13 | 2002-09-03 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US6369132B2 (en) * | 1997-10-17 | 2002-04-09 | Hercules Incorporated | Fine particle size low bulk density thermoplastic polymers |
US6444192B1 (en) * | 1999-02-05 | 2002-09-03 | The Regents Of The University Of California | Diagnostic imaging of lymph structures |
US6815170B1 (en) | 1999-06-30 | 2004-11-09 | John Wayne Cancer Institute | Methods for lymph node identification |
AU5905400A (en) | 1999-07-14 | 2001-02-05 | Board Of Regents, The University Of Texas System | Methods and compositions for delivery and retention of active agents to lymph nodes |
FR2835749B1 (en) * | 2002-02-08 | 2006-04-14 | Inst Nat Sante Rech Med | PHARMACEUTICAL COMPOSITION IMPROVING IN VIVO GENE TRANSFER |
US20040197264A1 (en) * | 2003-04-04 | 2004-10-07 | Alexander Schwarz | Microspheres comprising therapeutic and diagnostic radioactive isotopes |
CN101287507B (en) * | 2005-08-12 | 2012-12-05 | 刘江 | Methods and devices for lymphatic targeting |
CN105853394A (en) * | 2006-03-30 | 2016-08-17 | 恩根尼公司 | Non-viral compositions and methods for transfecting gut cells in vivo |
CA2660717A1 (en) * | 2006-08-17 | 2008-02-21 | Epix Pharmaceuticals, Inc. | Methods for lymph system imaging |
AU2010254550B2 (en) | 2009-05-27 | 2015-10-15 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with pH sensitive release of immunomodulatory agents |
AU2011258156B2 (en) | 2010-05-26 | 2016-11-24 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
US8815294B2 (en) | 2010-09-03 | 2014-08-26 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives and a carrier material |
AU2012290306B2 (en) | 2011-07-29 | 2017-08-17 | Selecta Biosciences, Inc. | Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses |
EP2968165B1 (en) | 2013-03-13 | 2023-09-13 | Biosphere Medical, Inc. | Compositions and associated methods for radioisotope-binding microparticles |
CN111514317B (en) * | 2020-04-09 | 2022-08-19 | 温州医科大学附属第一医院 | Lymphatic system bimodal imaging contrast agent |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH652599A5 (en) * | 1981-08-28 | 1985-11-29 | Solco Basel Ag | Method for producing colloidal physiological degradable, human serum albumin containing products and their use. |
GB8601100D0 (en) * | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
US5219577A (en) * | 1990-06-22 | 1993-06-15 | The Regents Of The University Of California | Biologically active composition having a nanocrystalline core |
JPH07509467A (en) * | 1992-07-21 | 1995-10-19 | ザ ゼネラル ホスピタル コーポレーション | Drug transport system to lymphoid tissue |
AU5355094A (en) * | 1992-10-14 | 1994-05-09 | Sterling Winthrop Inc. | Therapeutic and diagnostic imaging compositions and methods |
US5336507A (en) * | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
DE59403734D1 (en) * | 1993-03-17 | 1997-09-18 | Silica Gel Gmbh | SUPERPARAMAGNETIC PARTICLES, METHOD FOR THE PRODUCTION AND USE THEREOF |
US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5571536A (en) * | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5560931A (en) * | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
-
1992
- 1992-07-28 GB GB929216082A patent/GB9216082D0/en active Pending
-
1993
- 1993-07-28 WO PCT/GB1993/001596 patent/WO1994002122A1/en active IP Right Grant
- 1993-07-28 ES ES93917936T patent/ES2124791T3/en not_active Expired - Lifetime
- 1993-07-28 EP EP93917936A patent/EP0652746B1/en not_active Expired - Lifetime
- 1993-07-28 US US08/374,671 patent/US5792475A/en not_active Expired - Fee Related
- 1993-07-28 DK DK93917936T patent/DK0652746T3/en active
- 1993-07-28 AU AU47175/93A patent/AU4717593A/en not_active Abandoned
- 1993-07-28 JP JP6504329A patent/JPH08501534A/en active Pending
- 1993-07-28 GB GB9500063A patent/GB2283422B/en not_active Expired - Fee Related
- 1993-07-28 DE DE69321839T patent/DE69321839T2/en not_active Expired - Fee Related
-
1995
- 1995-01-23 NO NO950238A patent/NO307169B1/en unknown
-
1998
- 1998-06-15 US US09/094,959 patent/US5928669A/en not_active Expired - Fee Related
Non-Patent Citations (3)
Title |
---|
H. CARSTENSEN ET AL.: "adsorption of ethoxylated surfactants on nanoparticles. I. characterization by hydrophobic interaction chromatography", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 67, no. 1, 1991, pages 29 - 37 * |
J. S. TAN ET AL.: "protein adsorption and conformational change on small protein particles", JOURNAL OF COLLOID AND INTERFACE SCIENCE, vol. 136, no. 2, 1990, pages 415 - 431 * |
S. RUDT ET AL.: "in vitro phagocytosis assay of nano- and microparticles by chemiluminiscense. IV. effect of surface modification by coating of particles with poloxamine and antarox co on the phagocytic uptake", JOURNAL OF CONTROLLED RELEASE, vol. 25, no. 1/2, 27 May 1993 (1993-05-27), pages 123 - 132 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0601619A2 (en) * | 1992-12-04 | 1994-06-15 | NanoSystems L.L.C. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
EP0601619A3 (en) * | 1992-12-04 | 1995-11-02 | Sterling Winthrop Inc | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization. |
US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
WO1995003357A1 (en) * | 1993-07-23 | 1995-02-02 | Massachusetts Institute Of Technology | Biodegradable particles |
US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US6117454A (en) * | 1994-02-28 | 2000-09-12 | Medinova Medical Consulting Gmbh | Drug targeting to the nervous system by nanoparticles |
WO1995022963A1 (en) * | 1994-02-28 | 1995-08-31 | Medinova Medical Consulting Gmbh | Drug targeting system, method for preparing same and its use |
US6007845A (en) * | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US8097282B2 (en) | 1995-02-24 | 2012-01-17 | Alkermes Pharma Ireland Limited | Methods of administering liquid droplet aerosols of nanoparticulate drugs |
EP0859604A1 (en) * | 1995-09-29 | 1998-08-26 | NanoSystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
EP0859604A4 (en) * | 1995-09-29 | 2006-01-18 | Elan Pharma Int Ltd | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
US5611344A (en) * | 1996-03-05 | 1997-03-18 | Acusphere, Inc. | Microencapsulated fluorinated gases for use as imaging agents |
US9757464B2 (en) | 2009-03-05 | 2017-09-12 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives |
US9084727B2 (en) | 2011-05-10 | 2015-07-21 | Bend Research, Inc. | Methods and compositions for maintaining active agents in intra-articular spaces |
Also Published As
Publication number | Publication date |
---|---|
NO307169B1 (en) | 2000-02-21 |
NO950238L (en) | 1995-01-23 |
AU4717593A (en) | 1994-02-14 |
GB2283422A (en) | 1995-05-10 |
JPH08501534A (en) | 1996-02-20 |
DE69321839T2 (en) | 1999-04-15 |
GB9216082D0 (en) | 1992-09-09 |
GB2283422B (en) | 1996-05-01 |
US5928669A (en) | 1999-07-27 |
EP0652746B1 (en) | 1998-10-28 |
GB9500063D0 (en) | 1995-03-08 |
US5792475A (en) | 1998-08-11 |
DE69321839D1 (en) | 1998-12-03 |
DK0652746T3 (en) | 1999-07-12 |
EP0652746A1 (en) | 1995-05-17 |
ES2124791T3 (en) | 1999-02-16 |
NO950238D0 (en) | 1995-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0652746B1 (en) | Lymphatic delivery composition | |
US20210052507A1 (en) | Drugs and gene carrier particles that rapidly move through mucous barriers | |
US6207195B1 (en) | Therapeutic nanospheres | |
Godin et al. | Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation | |
JP2886171B2 (en) | Bioadhesive drug carriers for endothelial and epithelial uptake of therapeutic and diagnostic agents and localization to lesions | |
Müller | Colloidal carriers for controlled drug delivery and targeting: Modification, characterization and in vivo distribution | |
Bazile et al. | Body distribution of fully biodegradable [14C]-poly (lactic acid) nanoparticles coated with albumin after parenteral administration to rats | |
Coombes et al. | Biodegradable polymeric microparticles for drug delivery and vaccine formulation: the surface attachment of hydrophilic species using the concept of poly (ethylene glycol) anchoring segments | |
Bhadra et al. | PEGylated peptide dendrimeric carriers for the delivery of antimalarial drug chloroquine phosphate | |
EP2106806A1 (en) | Nanoparticles for targeted delivery of active agents to the lung | |
EP1233754A2 (en) | Targeted drug delivery with a cd44 receptor ligand | |
CA2395132A1 (en) | Pharmaceutical formulations for the delivery of drugs having low aqueous solubility | |
US20060270030A1 (en) | Multimodally altered cells as a form for administering active substances and as diagnostic particles | |
Lin et al. | Preparation of surface-modified albumin nanospheres | |
Song et al. | Surface-modified PLGA nanoparticles with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: Inhibition effects enhanced and side effects reduced | |
Nakamura et al. | Identification of polyethylene glycol-resistant macrophages on stealth imaging in vitro using fluorescent organosilica nanoparticles | |
TW200815047A (en) | Nanoparticle compositions | |
Lin et al. | Modulating drug release rate from partially silica-coated bicellar nanodisc by incorporating PEGylated phospholipid | |
Esim et al. | Albumin-based nanoparticles as promising drug delivery systems for cancer treatment | |
Ma et al. | Evaluation of blood circulation of polysaccharide surface-decorated PLA nanoparticles | |
Lahkar et al. | Surface modified polymeric nanoparticles for brain targeted drug delivery | |
CN112274654B (en) | Targeted drug-loaded nano-micelle, and preparation method and application thereof | |
Love et al. | Liposome association with inflammatory tissue | |
Douglas | for the degree of | |
WO1995000126A1 (en) | Surface-modified albumin microspheres and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI GB JP NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993917936 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08374671 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1993917936 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993917936 Country of ref document: EP |